Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.
Liu D et al.
Cancer Research Communications, 2025
Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor.
Ohtsubo K et al.
Frontiers in Oncology, 2025
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer.
Mishra R et al.
Molecular Carcinogenesis, 2024
Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.
Linder A et al.
Human Reproduction (oxford, England), 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.
Dey P et al.
International Journal of Biological Macromolecules, 2023
HER3 Alterations in Cancer and Potential Clinical Implications.
Kilroy MK et al.
Cancers, 2022
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.
Lyu D et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2022
Mutational landscape of normal epithelial cells in Lynch Syndrome patients.
Lee BCH et al.
Nature Communications, 2022
NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M et al.
Genes, 2021
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Pandey A et al.
Nature Communications, 2020
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.
Jin W
Journal of Clinical Medicine, 2020
A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G et al.
Molecular Medicine (cambridge, Mass.), 2020
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y et al.
Ebiomedicine, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N et al.
Oncogene, 2020
Identification of Altered Genes in Gallbladder Cancer as Potential Driver Mutations for Diagnostic and Prognostic Purposes: A Computational Approach.
D'Afonseca V et al.
Cancer Informatics, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
Systematic analysis of the intersection of disease mutations with protein modifications.
Simpson CM et al.
Bmc Medical Genomics, 2019
Prevalence and role of HER2 mutations in cancer.
Cocco E et al.
Pharmacology & Therapeutics, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
Loree JM et al.
Journal of the National Cancer Institute, 2018
The prognostic effects of somatic mutations in ER-positive breast cancer.
Griffith OL et al.
Nature Communications, 2018
Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer.
Rohan TE et al.
British Journal of Cancer, 2018
Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma.
Bankov K et al.
Clinical and Translational Gastroenterology, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS et al.
Cancer, 2018
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Elster N et al.
Therapeutic Advances in Medical Oncology, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Characterization of potential driver mutations involved in human breast cancer by computational approaches.
Rajendran BK et al.
Oncotarget, 2017
High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.
Hartmaier RJ et al.
Cancer Research, 2017
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR et al.
Genome Medicine, 2017
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
Comprehensive molecular portraits of human breast tumours.
Unknown Author
Nature, 2012